Testosterone oral - TesoRx

Drug Profile

Testosterone oral - TesoRx

Alternative Names: CDGP therapy - TesoRx; TSX-002

Latest Information Update: 26 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Western University of Health Sciences
  • Developer TesoRx
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone congener stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypogonadism
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypogonadism

Most Recent Events

  • 19 Jan 2017 Preclinical trials in Hypogonadism (In adolescents) in USA (PO)
  • 15 Apr 2016 TesoRx plans a clinical trial for Hypogonadism (In adolescents) in USA (TesoRx website, April 2016)
  • 01 Apr 2015 TesoRx Pharma completes a phase II trial in Hypogonadism (In adults) in USA (NCT02222558)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top